Karyopharm Therapeut (KPTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 146,067 | 145,237 | 146,033 | 157,074 | 209,819 |
| Cost of Goods | 5,949 | 6,007 | 4,942 | 5,213 | 3,402 |
| Gross Profit | 140,118 | 139,230 | 141,091 | 151,861 | 206,417 |
| Operating Expenses | 231,774 | 258,680 | 271,573 | 294,276 | 305,090 |
| Operating Income | -90,707 | -119,443 | -129,540 | -142,202 | -98,271 |
| Interest Expense | 45,849 | 37,422 | 23,823 | 24,996 | 26,046 |
| Other Income | -59,440 | 80,500 | 10,587 | 2,276 | 497 |
| Pre-tax Income | -195,996 | -76,365 | -142,776 | -164,922 | -123,820 |
| Income Tax | 43 | 57 | 323 | 369 | 268 |
| Net Income Continuous | -196,039 | -76,422 | -143,099 | -165,291 | -124,088 |
| Net Income | $-196,039 | $-76,422 | $-143,099 | $-165,291 | $-124,088 |
| EPS Basic Total Ops | -17.93 | -9.41 | -18.79 | -30.28 | -24.74 |
| EPS Basic Continuous Ops | -17.93 | -9.41 | -18.79 | -30.27 | -24.73 |
| EPS Diluted Total Ops | -17.93 | -14.00 | -18.79 | -30.28 | -24.74 |
| EPS Diluted Continuous Ops | -17.93 | -9.04 | -18.79 | -30.27 | -24.73 |
| EPS Diluted Before Non-Recurring Items | -12.23 | -13.94 | -18.74 | -30.29 | -24.74 |
| EBITDA(a) | $-80,275 | $-115,238 | $-132,294 | $-141,594 | $-95,142 |